Asset Details
Do you wish to reserve the book?
A pravastatin dose-escalation study in systemic lupus erythematosus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A pravastatin dose-escalation study in systemic lupus erythematosus
Do you wish to request the book?
A pravastatin dose-escalation study in systemic lupus erythematosus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A pravastatin dose-escalation study in systemic lupus erythematosus
2007
Overview
Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/-12.1%) and LDL by 24% (+/-17%), compared with 1.8% (+/-7.5%) and 2.6% (+/-8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.
Publisher
Springer Nature B.V
Subject
/ Cholesterol, LDL - drug effects
/ Dose-Response Relationship, Drug
/ Female
/ Glucocorticoids - therapeutic use
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Hypercholesterolemia - complications
/ Hypercholesterolemia - drug therapy
/ Lupus
/ Lupus Erythematosus, Systemic - complications
/ Lupus Erythematosus, Systemic - drug therapy
